NCT05826743

Brief Summary

The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
256

participants targeted

Target at P75+ for not_applicable

Timeline
10mo left

Started Dec 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Dec 2023Mar 2027

First Submitted

Initial submission to the registry

April 12, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 24, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

December 4, 2023

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2027

Last Updated

June 13, 2025

Status Verified

June 1, 2025

Enrollment Period

3 years

First QC Date

April 12, 2023

Last Update Submit

June 12, 2025

Conditions

Keywords

Colorectal SurgeryColorectal CancerStomaileostomyAnastomotic leakage

Outcome Measures

Primary Outcomes (1)

  • Study Success Case(Avoidance of ostomy)

    Study Success Case" is defined as a case which has met both the "Clinical Success" and "Technical Success" requirements throughout the 24 weeks (6 Months) monitoring period, following the initial surgical treatment with COLO-BT™ or temporary ileostomy

    24 Weeks

Study Arms (2)

COLO BT™

EXPERIMENTAL

Patients receive COLO BT™ during colorectal surgery.

Device: COLO BT™

Standard of Care

ACTIVE COMPARATOR

Patients receive the standard of care, a protective stoma, during colorectal surgery.

Other: Stoma Creation

Interventions

A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma after surgery for only patients who need it (do not have a healed anastomosis)

Also known as: COLO BT
COLO BT™

Protective ileostomy

Standard of Care

Eligibility Criteria

Age19 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adult males or females, 19-80 years of age, with signed informed consent
  • \- Male
  • \- Those with a body mass index of 30 or higher
  • \- Current smoker
  • \- Those who are on medication for diabetes
  • \- Those with clinical stage III or higher malignant tumors
  • \- Those who received chemo/radiation therapy before surgery
  • ④ Those who are willing and able to participate in this clinical study, provide Informed Consent, and are willing to comply with the study procedures and follow up evaluations
  • ⑤ Those who have willingness to undertake blood transfusion if required.

You may not qualify if:

  • Women who are pregnant or breastfeeding
  • Those who receive emergency surgery
  • A person who is expected to need intensive medical care after the surgery due to a serious medical condition, with one or more of the following seven factors being true:
  • Patients with abnormal bone marrow function (those with hemoglobin less than 7g/dl, leukocyte count less than 4000/mm3, or platelet count less than 100,000/mm3 even after preoperative corrections)
  • Patients with severe liver damage or cirrhosis (those whose AST/ALT levels are more than three times the normal range or those diagnosed with cirrhosis)
  • Those with abnormal renal function (those who are on hemodialysis or who have a blood creatinine level of 2.0mg/dl or more before the surgery)
  • Those who have undergone cardiac or cerebrovascular stent procedure within the last 6 months
  • Those who have been diagnosed with pulmonary tuberculosis within the last 6 months or are undergoing drug treatment for pulmonary tuberculosis
  • Those who continuously administer steroids of 20mg/day or more within 30 days before the surgery
  • Patients with ASA (American Society of Anesthesiologists) score of 3 are evaluated by the investigator who determines whether or not patients with ASA score of 3 should be enrolled from the patient safety standpoint. Patients with ASA score higher than 3 are excluded from this study.
  • Patients who are required to undergo re-intervention to treat the anastomosis following intraoperative positive air leak test (However, patients who underwent complete reconstruction of the anastomosis in the presence of a positive air test, which therefore has made their risk of leak similar to those patients with a negative air leak test.)
  • Patients who are immune suppressed
  • Patients with severe diverticulosis
  • Patients with other colonic wall abnormalities in the likely area of the Outer Balloon and BT BAND application who may be at increased risk for device perforation or migration.
  • A person who has difficulty in mobility or is unable to communicate in general due to a psychiatric/neurologic disorder falling under one or more of the following:
  • +14 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo

Buffalo, New York, 14203, United States

RECRUITING

PennState Health - Milton S. Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

RECRUITING

Baylor College of Medicine

Houston, Texas, 77030, United States

RECRUITING

MeSH Terms

Conditions

Colorectal NeoplasmsAnastomotic Leak

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Mark A Falvo, MD

    Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 12, 2023

First Posted

April 24, 2023

Study Start

December 4, 2023

Primary Completion (Estimated)

December 15, 2026

Study Completion (Estimated)

March 15, 2027

Last Updated

June 13, 2025

Record last verified: 2025-06

Locations